PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Lilly to collaborate with Precision BioSciences on genome editing research

Eli Lilly has entered a research collaboration and exclusive license agreement with Precision BioSciences to use genome editing to develop therapies for genetic disorders.

The lead programme and initial focus of the agreement will be on Duchenne muscular dystrophy (DMD), with two further undisclosed gene targets involved in the agreement.

Lilly will utilise Precision’s ARCUS genome editing platform, which is derived from a natural genome-editing enzyme called I-Crel, for the research and development of potential in vivo therapies for DMD and other genetic disorders.

As part of the deal, Precision will receive an upfront payment of $100m, with Lilly also making an equity investment of $35m in Precision’s common stock.

In addition, Precision is eligible to receive up to $420m in potential development and commercialisation milestones per product, as well as tiered royalties ranging from the mid-single digits to low-teens on product sales.

Under the research collaboration, Precision will lead pre-clinical research and IND-enabling activities, while Lilly will assume the responsibility for clinical development and commercialisation.

Lilly will also have the right to select up to three additional gene targets for this collaboration, with Precision retaining an option to co-fund clinical development of one product in return for an increased royalty rate on product sales.

“This collaboration with Precision BioSciences represents another milestone in the realisation of our vision to create medicines with transformational potential, using new therapeutic modalities such as gene editing to tackle targets and indications which were previously undruggable,” added Andrew Adams, vice president of new therapeutic modalities at Lilly.

“Collaborating with Lilly, a global healthcare leader with strong clinical and commercial experience in difficult-to-treat diseases, will help us accelerate our work aimed to solve genetic diseases with unique editing challenges,” added Derek Jantz, chief scientific officer and co-founder of Precision BioSciences

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026